Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Scilex Holding Company ( (SCLX) ) just unveiled an update.
Scilex Holding Company has announced a joint venture with IPMC Company to globally develop and commercialize KDS2010, a novel oral CNS compound in Phase 2 trials for treating obesity and neurodegenerative diseases, including Alzheimer’s disease. This venture positions Scilex to potentially redefine treatment standards in these areas with KDS2010, which has shown an innovative mechanism and favorable safety profile, offering a promising new treatment option for conditions where current therapies often fall short, amidst growing market opportunities for obesity and Alzheimer’s treatments.
More about Scilex Holding Company
Scilex Holding Company is an innovative, revenue-generating company focused on acquiring, developing, and commercializing treatments for neurodegenerative and cardiometabolic diseases, as well as non-opioid pain management products. Scilex targets indications with high unmet needs and large market opportunities, offering non-opioid therapies for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California, and its commercial products include ZTlido, ELYXYB, and Gloperba.
YTD Price Performance: -66.32%
Average Trading Volume: 2,026,752
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $131.8M
For detailed information about SCLX stock, go to TipRanks’ Stock Analysis page.
